The invention pertains to a composition for use in (a) treatment of impaired motor skills in a mammal suffering from Parkinson's Disease； (b) improving the efficacy of levodopa (L-DOPA) in treatment of impaired motor skills in a mammal suffering from Parkinson's Disease； and/or (c) reducing L-DOPA associated side effects, preferably involuntary movements selected from the group consisting of choreiform, dystonic and dyskinetic movements, in the treatment of impaired motor skills in a mammal suffering from Parkinson's Disease, comprising co-administering to the subject L-DOPA and a composition comprising therapeutically effective amounts of: (i) at least one of uridine, cytidine, or salts, phosphates, acyl derivatives or esters thereof； (ii) at least one of docosahexaenoic acid (22:6； DHA), eicosapentaenoic acid (20:5； EPA) and docosapentaenoic acid (22:5； DPA)； (iii) choline, or salts or esters thereof； and (iv) at least one vitamin B selected from vitamins B6, B9 and B12.
